• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Pharmacokinetics of rufloxacin in healthy volunteers.

作者信息

Segre G, Cerretani D, Moltoni L, Urso R

机构信息

Institute of Pharmacology, University of Siena, Italy.

出版信息

Eur J Clin Pharmacol. 1992;42(1):101-5. doi: 10.1007/BF00314928.

DOI:10.1007/BF00314928
PMID:1311685
Abstract

The plasma and urine kinetics of rufloxacin were assessed in healthy volunteers after single (100, 200, 400 and 800 mg) and multiple (300 mg followed by 150 mg daily, Group 1, and 400 mg followed by 200 mg daily, Group 2) oral doses. The kinetics of a single oral dose of 800 mg was assessed in fasting and non-fasting subjects to assess the influence of food intake on drug absorption. The AUCs were 134, 266 and 375 micrograms.h.ml-1 after 100, 200 and 400 mg, respectively. The AUC after 800 mg p.o. was 715 micrograms.h.ml-1 in fasting subjects and 614 micrograms.h.ml-1 in non-fasting subjects. The parameters of the model and the mean renal clearance values indicated some departure from linearity in rufloxacin kinetics. After multiple doses the plasma drug levels during the 6th treatment day were similar to those after the first dose in Group 1 and were about 30-40% higher after the first dose in Group 2. The half-lives after the last dose were much shorter than those estimated in the single dose studies (33-36 h and 50-80 h, respectively).

摘要

相似文献

1
Pharmacokinetics of rufloxacin in healthy volunteers.
Eur J Clin Pharmacol. 1992;42(1):101-5. doi: 10.1007/BF00314928.
2
Pharmacokinetics of rufloxacin in healthy volunteers after repeated oral doses.健康志愿者多次口服剂量后芦氟沙星的药代动力学
Chemotherapy. 1991;37(6):389-97. doi: 10.1159/000238885.
3
Multiple-dose pharmacokinetics and safety of rufloxacin in normal volunteers.鲁氟沙星在正常志愿者中的多剂量药代动力学及安全性
Antimicrob Agents Chemother. 1992 Jun;36(6):1296-301. doi: 10.1128/AAC.36.6.1296.
4
Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.长效喹诺酮类抗菌剂鲁氟沙星的药代动力学及组织穿透性
J Antimicrob Chemother. 1991 Dec;28(6):905-9. doi: 10.1093/jac/28.6.905.
5
Biliary excretion of rufloxacin in humans.鲁氟沙星在人体中的胆汁排泄。
Antimicrob Agents Chemother. 1993 Dec;37(12):2545-9. doi: 10.1128/AAC.37.12.2545.
6
Multiple-dose pharmacokinetics of rufloxacin in patients with cirrhosis.肝硬化患者中芦氟沙星的多剂量药代动力学
Hepatology. 1993 Oct;18(4):847-52. doi: 10.1002/hep.1840180415.
7
Pharmacokinetics and tolerance of DU-6859a, a new fluoroquinolone, after single and multiple oral doses in healthy volunteers.新型氟喹诺酮类药物DU-6859a在健康志愿者单次及多次口服给药后的药代动力学及耐受性
Antimicrob Agents Chemother. 1995 Jan;39(1):170-4. doi: 10.1128/AAC.39.1.170.
8
Pharmacokinetics of rufloxacin in patients with impaired renal function.肾功能受损患者中芦氟沙星的药代动力学
Antimicrob Agents Chemother. 1993 Apr;37(4):637-41. doi: 10.1128/AAC.37.4.637.
9
Steady-state pharmacokinetics of rufloxacin in elderly patients with lower respiratory tract infections.
Ther Drug Monit. 1992 Feb;14(1):36-41. doi: 10.1097/00007691-199202000-00006.
10
Inter- and intrasubject variabilities in the pharmacokinetics of rufloxacin after single oral administration to healthy volunteers.健康志愿者单次口服芦氟沙星后的药代动力学的个体间和个体内变异性。
Antimicrob Agents Chemother. 1991 Feb;35(2):390-3. doi: 10.1128/AAC.35.2.390.

引用本文的文献

1
Together or Apart? Revealing the Impact of Dietary Interventions on Bioavailability of Quinolones: A Systematic Review with Meta-analyses.联合或分开?揭示饮食干预对喹诺酮类药物生物利用度的影响:系统评价与荟萃分析。
Clin Pharmacokinet. 2024 Jun;63(6):773-818. doi: 10.1007/s40262-024-01377-0. Epub 2024 May 28.
2
Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials.新型氟喹诺酮类抗菌药物的比较药代动力学与药效学
Clin Pharmacokinet. 2001;40(3):169-87. doi: 10.2165/00003088-200140030-00003.

本文引用的文献

1
Quinolonecarboxylic acids. 2. Synthesis and antibacterial evaluation of 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzothiazine-6-carboxylic acids.喹诺酮羧酸。2. 7-氧代-2,3-二氢-7H-吡啶并[1,2,3-de][1,4]苯并噻嗪-6-羧酸的合成与抗菌活性评价
J Med Chem. 1987 Mar;30(3):465-73. doi: 10.1021/jm00386a005.
2
A new tricyclic fluoroquinolone, rufloxacin (MF-934), with interesting antibacterial and pharmacokinetic characteristics.一种新型三环氟喹诺酮类药物鲁氟沙星(MF - 934),具有引人关注的抗菌及药代动力学特性。
Drugs Exp Clin Res. 1988;14(12):747-54.